TAZORAC (tazarotene) by Almirall is form, the carboxylic acid of tazarotene, by deesterification. Approved for retinoid [epc]. First approved in 2000.
Drug data last refreshed 56m ago · AI intelligence enriched 56m ago
TAZORAC (tazarotene) is a topical retinoid cream approved in 2000 that binds to retinoic acid receptors (RARα, RARβ, RARγ) with relative selectivity for RARβ and RARγ to modify gene expression. It is indicated for acne and psoriasis treatment via topical application. The drug works by normalizing keratinocyte differentiation and reducing inflammation in affected skin.
Product is in late-stage lifecycle with modest Medicare spending; commercial teams face margin compression and limited growth opportunities.
form, the carboxylic acid of tazarotene, by deesterification. Tazarotenic acid binds to all three members of the retinoic acid receptor (RAR) family: RARα, RARβ, and RARɣ, but shows relative selectivity for RARβ, and RARɣ and may modify gene expression. The clinical significance of these findings…
Retinoid
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis
Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions
A Bioavailability Study of DFD-03 Compared to Tazorac® in Patients With Moderate Acne Vulgaris
A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® Cream, 0.1% in the Topical Treatment of Acne Vulgaris
Absorption and Systematic Pharmacokinetics of IDP-123 Lotion in Comparison With Tazorac Cream
Worked on TAZORAC at Almirall? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moTAZORAC offers limited career growth potential due to LOE approaching status and fragmentation by competing formulations and generic alternatives. Roles focus on defending market share and managing decline rather than expansion and innovation.